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With 10 years left to the WHO End TB Strategy’s interim milestones of 80% reduction in new tuberculosis cases and 
90% reduction in tuberculosis deaths by 2030 compared with 2015,1 little progress has been made. The 
COVID-19 pandemic has worsened the situation because of its negative impact on tuberculosis case detection 
and reduced access to tuberculosis treatment and prevention services globally.2 In a worst-case scenario, 
COVID-19 might have resulted in up to 400 000 excess tuberculosis deaths in 2020, which would mean the 
worldwide number was similar to that in 2012.3 Estimates suggest that the  COVID-19 pandemic could 
cause an additional 6·3 million tuberculosis cases globally between 2020 and 2025, with the most vulnerable 
populations, especially children, at risk.4 These extreme outcomes would slow or reverse any progress made towards 
the tuberculosis treatment and prevention milestones and targets.5,6 
WHO estimated that children younger than 15 years constituted 12% of the 10 million people who became ill with 
tuberculosis in 2019.4 The global annual numbers of tuberculosis cases accounted for by children have been on 
the rise, increasing  from  about  1  million in 2017 to 1·2 million in 2019,4,7 with the highest burden of childhood 
tuberculosis in China, the Democratic Republic of the Congo, India, Indonesia, and Nigeria.8 Despite the global 
efforts to combat tuberculosis, an estimated 192 000 children died from tuberculosis  in 2019.4 The high burden 
of childhood tuberculosis and poor outcomes are largely because of the difficulties in confirming the diagnosis of 
tuberculosis in children, arising from the non-specific nature of symptoms and signs of tuberculosis in children, the 
paucibacillary nature of childhood tuberculosis, the challenge of obtaining good-quality sputum samples, 
especially in young children, and difficulties in accessing health services.9 As a result, more than 90% of these 
children encounter delays in receiving treatment since they are either never diagnosed or are misdiagnosed.7 An 
estimated 568 000 missing childhood tuberculosis cases in 2019 were neither diagnosed nor adequately treated.4 
A fundamental problem is the absence of large-scale contact screening and provision of tuberculosis preven- tive 
therapy to eligible children, which is largely due to insufficient health-care resources, workforce, and services 
in low-income and middle-income countries (LMICs).4 In 2019, more than 40% of eligible household child contacts 
were not screened for tuberculosis disease or infection.4 Therefore, access to and provision of tuberculosis contact 
screening and preventive treatment needs to be substantially expanded. 
Alongside efforts to address multidrug-resistant tuberculosis in children and deliver less toxic and more child-
friendly tuberculosis treatments,7 improving child- hood tuberculosis case detection is crucial. Efforts to prioritise 
case detection will also benefit from innovative community-based approaches to case finding, such as the need for 
enhanced screening for tuberculosis in children presenting at general child health services in LMICs. Given that 
many children with presumptive tuberculosis present to maternal and child health clinics and private care providers 
in LMICs,10 a close interaction between tuberculosis programmes and these services is needed. This approach is 
essential to reach the over 60% of children who acquire the infection outside the household and who would 
not be reached by household contact-based approaches, even with the most optimistic assumptions for coverage 
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of household contact tracing.11 
Tuberculosis testing is reliant on sputum, a sample that is not easy to collect, especially in young children. 
Additionally, WHO-recommended rapid tuberculosis diagnostic tests such as Xpert-Ultra are not easily 
accessible at the primary care level in LMICs where they are most needed.7 The development of non-sputum 
biomarker-based tests for diagnosis of tuberculosis, especially in children who are typically paucibacillary, is now 
a recognised research priority.12 
To achieve the WHO End TB Strategy targets and narrow the childhood tuberculosis case detection gap, 
tuberculosis vaccines are needed that are effective for both pre-exposure and post-exposure prevention and 
treatment.13 COVID-19 has shown how several efficacious vaccines can be developed within a short 
timeframe, given the right motivation and available funding. The BCG vaccine, which was developed 100 
years ago, effectively prevents severe forms of the disease but has only moderate benefits for prevention of 
pulmonary tuberculosis.14 Having new tuberculosis vaccines would help reduce new tuberculosis cases and 
deaths. Given the demonstrated ability to develop effective COVID-19 vaccines rapidly, it is no longer 
justifiable to not equally invest in the development of tuberculosis vaccines. 
To accelerate progress toward ending tuberculosis, there is the need for sustained increase in investments in 
tuberculosis control services that are delivered as part of comprehensive primary health-care services, and for 
strengthening health workforce capacity and health systems as part of overall efforts toward achieving 
universal health coverage in LMICs. Therefore, as we mark World Tuberculosis Day on March 24, 2021, the theme— The 
Clock is Ticking—is apt to convey a sense of urgency. As countries move towards recovery from the setbacks caused 
by COVID-19, it is a pivotal moment to make tuberculosis case detection in children a priority. The next few 
years will be  crucial  in the  tuberculosis response, and it will take sustained efforts by many stakeholders to achieve 
the internationally agreed targets by 2030. Tuberculosis is preventable and treatable and no child with tuberculosis 
should miss out on the care they need. 
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